OS Therapies Inc
OST-HER2
osteosarcoma
Date
TBD
Phase 3 readout · Date TBD estimated
What's at stake
Phase 3 trial results for OST-HER2 in osteosarcoma are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 13h ago
“the Company is seeking to obtain a BLA under the Accelerated Approval Program for OST-HER2 in osteosarcoma by year-end 2026 in the U.S.”